Indications
Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control.
Composition
- Active substance
- insulin degludec, liraglutide
- International name (INN)
- insulin degludec;liraglutide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xultophy
- Active substance
- insulin degludec, liraglutide
- ATC code
- A10AE56
- Therapeutic area
- Diabetes Mellitus, Type 2